{"fetched":"2026-10-29","feeds":[{"id":"fda-oce","name":"FDA Oncology Center of Excellence","homepage":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","kind":"regulator","sourceId":"fda-approvals","ok":true,"count":12},{"id":"nejm","name":"New England Journal of Medicine","homepage":"https://www.nejm.org/","url":"https://www.nejm.org/action/showFeed?type=etoc&feed=rss&jc=nejm","kind":"journal","sourceId":"nejm","onlyOncology":true,"ok":true,"count":5},{"id":"lancet-oncology","name":"The Lancet Oncology","homepage":"https://www.thelancet.com/journals/lanonc/home","url":"https://www.thelancet.com/rssfeed/lanonc_current.xml","kind":"journal","sourceId":"lancet-oncology","ok":true,"count":37},{"id":"jco","name":"Journal of Clinical Oncology","homepage":"https://ascopubs.org/journal/jco","url":"https://ascopubs.org/action/showFeed?type=etoc&feed=rss&jc=jco","kind":"journal","sourceId":"jco","ok":true,"count":40},{"id":"nature-medicine","name":"Nature Medicine","homepage":"https://www.nature.com/nm/","url":"https://www.nature.com/nm.rss","kind":"journal","sourceId":"nature-medicine","onlyOncology":true,"ok":false,"count":2,"error":"response is not a supported feed; showing 2 items from 2026-10-22"},{"id":"endpoints","name":"Endpoints News","homepage":"https://endpts.com/","url":"https://endpts.com/feed/","kind":"news","sourceId":"src-endpoints-news","onlyOncology":true,"ok":true,"count":3},{"id":"stat","name":"STAT","homepage":"https://www.statnews.com/","url":"https://www.statnews.com/feed/","kind":"news","sourceId":"src-stat-news","onlyOncology":true,"ok":true,"count":1}],"items":[{"feedId":"lancet-oncology","title":"[Editorial] Sweating the details in exercise oncology","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00546-2/fulltext","date":"2026-11-01","refs":["prostate","challenge","exercise-oncology"]},{"feedId":"lancet-oncology","title":"[Comment] Iberdomide for minimal residual disease-negative myeloma—from underdog to the spotlight","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00521-8/fulltext","date":"2026-11-01","refs":["celmods","multiple-myeloma","lenalidomide","pomalidomide","thalidomide","iberdomide","cereblon","ikzf1"]},{"feedId":"lancet-oncology","title":"[Comment] Comprehensiveness of national cancer control plans","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00541-3/fulltext","date":"2026-11-01","refs":["a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[Comment] The unfulfilled promise of effective cancer medicines priced beyond reach","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00533-4/fulltext","date":"2026-11-01","refs":["metastatic-pdac","pancreatic","nct07353645","nct07381309","daraxonrasib","nct05035745","nct06590246"]},{"feedId":"lancet-oncology","title":"[Comment] Rare earth elements and the fragile promise of cancer theranostics","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00486-9/fulltext","date":"2026-11-01","refs":["neuroendocrine","prostate"]},{"feedId":"lancet-oncology","title":"[Correspondence] From biomarker actionability to surveillance utility in SERENA-6","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00440-7/fulltext","date":"2026-11-01","refs":["camizestrant","nct06936774","aromatase","serena-6","nct05281471","nct06463665"]},{"feedId":"lancet-oncology","title":"[Correspondence] BCG-unresponsive non-muscle-invasive bladder cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00511-5/fulltext","date":"2026-11-01","refs":["non-muscle-invasive-bladder-cancer","cretostimogene","bond-003","urothelial"]},{"feedId":"lancet-oncology","title":"[Correspondence] BCG-unresponsive non-muscle-invasive bladder cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00512-7/fulltext","date":"2026-11-01","refs":["non-muscle-invasive-bladder-cancer","cretostimogene","bond-003","nct05281471","nct06463665","urothelial"]},{"feedId":"lancet-oncology","title":"[Correspondence] BCG-unresponsive non-muscle-invasive bladder cancer – Authors’ reply","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00525-5/fulltext","date":"2026-11-01","refs":["non-muscle-invasive-bladder-cancer","bond-003","urothelial"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2025; 26: 898–910","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00543-7/fulltext","date":"2026-11-01","refs":["breast-cancer","nct06949111","import-low"]},{"feedId":"lancet-oncology","title":"[Corrections] Correction to Lancet Oncol 2025; 26: e423–35","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00474-2/fulltext","date":"2026-11-01","refs":[]},{"feedId":"lancet-oncology","title":"[Perspectives] Beyond words: the Art of Living","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00467-5/fulltext","date":"2026-11-01","refs":[]},{"feedId":"lancet-oncology","title":"[Perspectives] Alison Berner: Connecting oncology and gender medicine","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00545-0/fulltext","date":"2026-11-01","refs":[]},{"feedId":"lancet-oncology","title":"[Perspectives] There is beauty after breast cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00466-3/fulltext","date":"2026-11-01","refs":["breast-cancer"]},{"feedId":"lancet-oncology","title":"[Articles] Assessment of comprehensiveness of national cancer control plans using a multiagent artificial intelligence model: a global analysis","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00281-0/fulltext","date":"2026-11-01","refs":["a16z-bio-health","nct07219576","precision-promise"]},{"feedId":"lancet-oncology","title":"[Articles] Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00290-1/fulltext","date":"2026-11-01","refs":["zamtocabtagene-autoleucel","car-t","non-hodgkin-lymphoma","bcl10","bcl11b","nct05704049","nct01827605","nct04844866"]},{"feedId":"lancet-oncology","title":"[Policy Review] Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivors","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00340-2/fulltext","date":"2026-11-01","refs":["childrens-oncology-group","mds"]},{"feedId":"lancet-oncology","title":"[Policy Review] Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00347-5/fulltext","date":"2026-11-01","refs":["recurrent-metastatic-nasopharyngeal-carcinoma","nasopharyngeal"]},{"feedId":"endpoints","title":"Pfizer India site closure risks exacerbating cancer drug shortages","url":"https://endpoints.news/pfizer-india-site-closure-risks-exacerbating-cancer-drug-shortages/","date":"2026-10-28","refs":["pfizer"]},{"feedId":"endpoints","title":"Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences","url":"https://endpoints.news/astellas-buys-option-to-preclinical-il-12-cancer-drug-from-audax-biosciences/","date":"2026-10-28","refs":["astellas","adienne"]},{"feedId":"jco","title":"Art as a Shared Space: Tracing the Unseen Through a Body Map","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01143","date":"2026-10-27","refs":[]},{"feedId":"endpoints","title":"Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO","url":"https://endpoints.news/outpace-ends-an-ovarian-cancer-trial-incyte-data-impresses-at-esmo/","date":"2026-10-27","refs":["ovarian","mesothelin","eb-mf-car-nk-01","nct07218003","nct07491497","nct05180799","nct06480565","nct05585320"]},{"feedId":"stat","title":"STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down","url":"https://www.statnews.com/2026/10/27/autoimmune-cell-therapy-trial-artiva-therapeutics-shutting-down/?utm_campaign=rss","date":"2026-10-27","refs":[]},{"feedId":"fda-oce","title":"FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive","date":"2026-10-26","refs":["prostate","enzalutamide","talazoparib","pfizer","beone"]},{"feedId":"lancet-oncology","title":"[Articles] Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00446-8/fulltext","date":"2026-10-25","refs":["rectal-cancer","colorectal","camrelizumab-rivoceranib","camrelizumab","nct07381309","nct06949111","nct05562297","nct07412613"]},{"feedId":"nejm","title":"Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2608323?af=R&rss=currentIssue","date":"2026-10-24","refs":["enfortumab-vedotin","tremelimumab","durvalumab","urothelial"]},{"feedId":"nejm","title":"Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2609482?af=R&rss=currentIssue","date":"2026-10-24","refs":["extensive-stage-sclc","sclc","lung-cancer","durvalumab","tarlatamab"]},{"feedId":"nejm","title":"Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2610345?af=R&rss=currentIssue","date":"2026-10-24","refs":["breast-cancer","nct05035745","nct06590246","hb1801","her2"]},{"feedId":"nejm","title":"Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMc2611022?af=R&rss=currentIssue","date":"2026-10-21","refs":["metastatic-pdac","pancreatic","nct07353645","daraxonrasib"]},{"feedId":"nature-medicine","title":"Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial","url":"https://www.nature.com/articles/s41591-026-04757-0","date":"2026-10-20","refs":["myeloma-relapsed-refractory","nct03915184","nct05862012","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer","date":"2026-10-19","refs":["rectal-cancer","mmr","colorectal","dostarlimab","nct04655976","nct05035745","nct06590246"]},{"feedId":"nature-medicine","title":"Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy","url":"https://www.nature.com/articles/s41591-026-04692-0","date":"2026-10-19","refs":["multiple-myeloma"]},{"feedId":"fda-oce","title":"FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph","date":"2026-10-16","refs":["nct04652076","nct06976944","nct04153734","pembrolizumab","nct05224141","merck","alfa"]},{"feedId":"lancet-oncology","title":"[News] Europe has fallen behind in number of oncology trials","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00555-3/fulltext","date":"2026-10-15","refs":[]},{"feedId":"lancet-oncology","title":"[News] Russia slashes federal cancer funding to spend on defence","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00556-5/fulltext","date":"2026-10-15","refs":["spen"]},{"feedId":"jco","title":"Expert Histopathologic Evaluation and Molecular Analyses for Ambiguous Cutaneous Melanocytic Tumors","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00432","date":"2026-10-15","refs":[]},{"feedId":"fda-oce","title":"FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle","date":"2026-10-14","refs":["nogapendekin-alfa","immunitybio","urothelial","non-muscle-invasive-bladder-cancer","beone","alfa"]},{"feedId":"jco","title":"Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-03013","date":"2026-10-14","refs":["selpercatinib","nct03899792","nct05281471","nct06463665","nct02802423","nct06861452","nct06149481","nct07063329"]},{"feedId":"jco","title":"The Boy Who Became a Tiger","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00001","date":"2026-10-13","refs":[]},{"feedId":"jco","title":"VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00992","date":"2026-10-13","refs":["polycythaemia-vera","rusfertide","nct07221474","verify"]},{"feedId":"jco","title":"Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer—The Copenhagen Lung Cancer Risk Model (CPH-Lung)","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02326","date":"2026-10-12","refs":["lung-cancer"]},{"feedId":"jco","title":"Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00474","date":"2026-10-12","refs":[]},{"feedId":"lancet-oncology","title":"[Comment] Time to say goodbye to full-field digital mammography in population-based screening?","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00524-3/fulltext","date":"2026-10-09","refs":["breast-cancer","mammography"]},{"feedId":"lancet-oncology","title":"[Articles] Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00341-4/fulltext","date":"2026-10-09","refs":["mammography","breast-cancer","nct00376883"]},{"feedId":"jco","title":"Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02995","date":"2026-10-09","refs":["prostate-mcrpc","androgen-receptor","prostate","nct02802423","nct06861452","nct06149481","nct07063329","nct06110572"]},{"feedId":"fda-oce","title":"FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer","date":"2026-10-08","refs":["mmr","nct04434040","nct07381309","atezolizumab","colon-cancer","nct06782685","oxaliplatin","roche-genentech"]},{"feedId":"lancet-oncology","title":"[News] Impact of the Trump Administration on the Affordable Care Act","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00540-1/fulltext","date":"2026-10-08","refs":["a16z-bio-health"]},{"feedId":"jco","title":"RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00725","date":"2026-10-08","refs":["varegacestat","nct05744687","nct04871282","nct07290088"]},{"feedId":"jco","title":"Prognostic Impact of Telomere Maintenance Mechanisms in Neuroblastoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00742","date":"2026-10-08","refs":["neuroblastoma"]},{"feedId":"fda-oce","title":"FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer","date":"2026-10-07","refs":["breast-her2-positive","breast-cancer","trastuzumab","nct06891833","pertuzumab","nct04514419","tucatinib","nct05035745"]},{"feedId":"lancet-oncology","title":"[Articles] Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00387-6/fulltext","date":"2026-10-07","refs":["high-grade-serous-ovarian-cancer","ovarian","nct07381309","nct05562297","nct07412613","niraparib","platinum-etoposide","nct05035745"]},{"feedId":"jco","title":"NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00201","date":"2026-10-07","refs":["breast-cancer","nct05744687","nct07290088"]},{"feedId":"jco","title":"Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00670","date":"2026-10-06","refs":[]},{"feedId":"fda-oce","title":"FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic","date":"2026-10-02","refs":["apex-03","nct06943872","nct02966756","nct06588478","nct05023980","nct05254743","nct04965493","pirtobrutinib"]},{"feedId":"jco","title":"Clinical Practice Guideline for Systemic Antibacterial and Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Cell Transplant Recipients: 2026 Update","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00720","date":"2026-10-02","refs":[]},{"feedId":"lancet-oncology","title":"[News] Could Brazil's tuberculosis network detect lung cancer earlier?","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00527-9/fulltext","date":"2026-10-01","refs":["bms","lung-cancer","a16z-bio-health","nct00376883"]},{"feedId":"lancet-oncology","title":"[News] New UK National Cancer Board","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00528-0/fulltext","date":"2026-10-01","refs":[]},{"feedId":"lancet-oncology","title":"[News] Viet Nam considers health insurance for cancer screening","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00529-2/fulltext","date":"2026-10-01","refs":["a16z-bio-health"]},{"feedId":"lancet-oncology","title":"[News] 2026 ASTRO Annual Meeting","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00530-9/fulltext","date":"2026-10-01","refs":["extensive-stage-sclc","sclc","nct06936774","lung-cancer","nct04155034","nct07728955","nct06441344","swog"]},{"feedId":"jco","title":"Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00247","date":"2026-09-30","refs":[]},{"feedId":"lancet-oncology","title":"[Policy Review] Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00333-5/fulltext","date":"2026-09-29","refs":["curie-nki-eortc","a16z-bio-health"]},{"feedId":"jco","title":"Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01114","date":"2026-09-29","refs":["sentinel-node","breast-cancer","nct07381309","nct05562297","nct07412613","nct05035745","nct06590246"]},{"feedId":"jco","title":"Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00735","date":"2026-09-29","refs":["brca"]},{"feedId":"lancet-oncology","title":"[Articles] Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00450-X/fulltext","date":"2026-09-25","refs":["myeloma-relapsed-refractory","nct03915184","nct05862012","nct06413498","nct06235229","nct07284758","nct06566547","nct06115135"]},{"feedId":"lancet-oncology","title":"[Articles] Global uptake of essential cancer medicines with and without complex genomic diagnostics: a retrospective observational study","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00432-8/fulltext","date":"2026-09-25","refs":[]},{"feedId":"jco","title":"Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00401","date":"2026-09-25","refs":["multiple-myeloma","dexamethasone","lenalidomide","daratumumab","bortezomib","cepheus"]},{"feedId":"fda-oce","title":"FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component","date":"2026-09-24","refs":["rcc","lenvatinib","nct04875585","belzutifan","nct04924075","nct05035745","nct06590246","eisai"]},{"feedId":"lancet-oncology","title":"[News] 70th IAEA General Conference","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00513-9/fulltext","date":"2026-09-24","refs":["brachytherapy","nct07381309","nct06949111"]},{"feedId":"lancet-oncology","title":"[News] India reaches 8 million milestone in HPV campaign","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00514-0/fulltext","date":"2026-09-24","refs":["cervical","hpv-quadrivalent-vaccine","a16z-bio-health","nct00376883"]},{"feedId":"lancet-oncology","title":"[News] US EPA repeals emission limits","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00515-2/fulltext","date":"2026-09-24","refs":[]},{"feedId":"jco","title":"First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2–Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02933","date":"2026-09-24","refs":["egf","retlirafusp-alfa","urethral-adenocarcinoma","lung-adenocarcinoma","nct07381309","gastric","gdf7","alfa"]},{"feedId":"fda-oce","title":"FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic","date":"2026-09-23","refs":["elevar-therapeutics","lirafugratinib","nct05035745","nct06590246","gdf7","fgfr2","beone"]},{"feedId":"jco","title":"Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00017","date":"2026-09-23","refs":["cholangiocarcinoma","biliary-tract-cancer","ascot-jcog1202","scot"]},{"feedId":"lancet-oncology","title":"[Articles] Global health expenditures on cancer control: a cross-sectional analysis","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00354-2/fulltext","date":"2026-09-22","refs":["a16z-bio-health"]},{"feedId":"jco","title":"When Survival Separates","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00371","date":"2026-09-22","refs":[]},{"feedId":"jco","title":"Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02766","date":"2026-09-22","refs":["melanoma","braf"]},{"feedId":"jco","title":"Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02476","date":"2026-09-21","refs":["ductal-carcinoma-in-situ"]},{"feedId":"fda-oce","title":"FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or","date":"2026-09-18","refs":["breast-hr-positive","nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886"]},{"feedId":"jco","title":"Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02737","date":"2026-09-18","refs":["a16z-bio-health"]},{"feedId":"jco","title":"Erratum: Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-02285","date":"2026-09-17","refs":["cancer-of-unknown-primary","nct07381309","nct05744687","nct05281471","nct06463665","nct07290088","cupisco"]},{"feedId":"jco","title":"Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-01967","date":"2026-09-16","refs":[]},{"feedId":"jco","title":"Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-02254","date":"2026-09-16","refs":["egf","trastuzumab-rezetecan","trastuzumab","nct06891833","nct05035745","nct05749900","nct05744687","nct06590246"]},{"feedId":"jco","title":"Erratum: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-02255","date":"2026-09-16","refs":["gvhd-prophylaxis","nct06771609","cyclophosphamide"]},{"feedId":"jco","title":"Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA–Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01914","date":"2026-09-16","refs":["nct07095309","nct05954078","colorectal","nct06936774"]},{"feedId":"lancet-oncology","title":"[Comment] Why childhood cancer medicines need market shaping led by the Global Platform: toward market transformation","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00454-7/fulltext","date":"2026-09-15","refs":["trrap","a16z-bio-health"]},{"feedId":"jco","title":"Can Biomarkers Effectively Guide Treatment Tailoring in Human Epidermal Growth Factor 2–Positive Early Breast Cancer?","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01857","date":"2026-09-15","refs":["egf","breast-cancer","gdf7"]},{"feedId":"jco","title":"Retraction: Palliative Care Involvement at the End of Life in Advanced Cancer","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-02300","date":"2026-09-15","refs":["metastatic-cancer","nct05035745","nct06590246"]},{"feedId":"jco","title":"Recent Population-Level Trends in Utilization of Outpatient Medical Oncology Services","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01156","date":"2026-09-15","refs":[]},{"feedId":"jco","title":"Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00785","date":"2026-09-15","refs":[]},{"feedId":"jco","title":"Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00285","date":"2026-09-15","refs":["childrens-oncology-group","ewing-sarcoma"]},{"feedId":"jco","title":"Bridging the Gap: Precision Oncology for Cancers of Unknown Primary","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01847","date":"2026-09-14","refs":[]},{"feedId":"nejm","title":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2610229?af=R&rss=currentIssue","date":"2026-09-12","refs":["sclc","yl201","lung-cancer","platinum-etoposide"]},{"feedId":"jco","title":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00602","date":"2026-09-11","refs":["egf","trastuzumab-emtansine","breast-cancer","trastuzumab","nct06891833","nct05035745","nct06590246","gdf7"]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small","date":"2026-09-09","refs":["nct05318573","sevabertinib","lung-cancer","nct05035745","lung-squamous-cell-carcinoma","nct06590246","nsclc","nct06745882"]},{"feedId":"jco","title":"Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00769","date":"2026-09-09","refs":["nct06976944","nct04153734","pembrolizumab","nct05224141","nct06949111","sarcoma"]},{"feedId":"jco","title":"LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00451","date":"2026-09-09","refs":["dlbcl","high-grade-b-cell-lymphoma-myc-bcl2","nct05487170","non-hodgkin-lymphoma","bcl10","bcl11b","adult-t-cell-leukaemia-lymphoma","jcog9801"]},{"feedId":"jco","title":"Purple Blossoms","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-00469","date":"2026-09-08","refs":[]},{"feedId":"fda-oce","title":"FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative","date":"2026-09-04","refs":["nct06561607","nct07678957","nct06202261","nct07497386","nct07558733","nct06702618","nct06957886","egf"]},{"feedId":"jco","title":"Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study","url":"https://ascopubs.org/doi/abs/10.1200/JCO-25-02974","date":"2026-09-03","refs":["cancer-of-unknown-primary","nct07381309","nct05744687","nct05281471","nct06463665","nct07290088","cupisco"]},{"feedId":"jco","title":"Bridging the Gap: Clinical Integration of Thrombopoietin Receptor Agonists in GI Cancer–Associated Chemotherapy-Induced Thrombocytopenia","url":"https://ascopubs.org/doi/abs/10.1200/JCO-26-01447","date":"2026-09-01","refs":["nct07381309"]}]}